Management and Outcomes of Relapse After Treatment for Thymoma and Thymic Carcinoma

被引:45
|
作者
Bott, Matthew J.
Wang, Hanghang
Travis, William
Riely, Gregory J.
Bains, Manjit
Downey, Robert
Rusch, Valerie
Huang, James [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Thorac Serv, Dept Surg, Dept Pathol, New York, NY 10065 USA
来源
ANNALS OF THORACIC SURGERY | 2011年 / 92卷 / 06期
关键词
CLINICOPATHOLOGICAL FEATURES; STAGE-III; FOLLOW-UP; RECURRENCE; CHEMOTHERAPY; REOPERATION; RESECTION; THERAPY; TUMORS;
D O I
10.1016/j.athoracsur.2011.07.078
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Although surgery is the mainstay of treatment for thymic tumors, recurrence is common despite resection. The optimal approach to the management of disease relapse after treatment for thymic tumors remains unclear. Methods. This study is a retrospective analysis of a single-institution experience assessing treatment patterns and outcomes in patients with recurrence or disease progression after surgical treatment for thymic tumors. Data included demographics, stage, treatment, pathologic findings, and postoperative outcomes. Results. From 1995 to 2006, 120 patients had initial resection of a thymic tumor at our institution, of which 112 had recurrence data available. Twenty-five patients developed recurrence or progression of disease after their initial resection (10 thymic carcinoma, 15 thymoma). Median follow-up was 51.4 months. Higher Masaoka stages predominated (I: 0; II: 4; III: 8; IV: 13). Eleven patients (44%) underwent surgery for their relapse with curative intent, while 14 (56%) were managed nonsurgically. Surgery was considered when disease was intrathoracic, unilateral, and technically resectable. The 11 patients receiving surgery had a total of 16 reoperations (range 1 to 4). An R0 re-resection was obtained in half of cases (8 of 16, 50%) but the majority of operative patients (9 of 11, 82%) recurred again. The 5-year overall survival of the 25 patients with recurrent or persistent disease was 58% (median survival = 82 months). Kaplan-Meier curves demonstrate a trend (p = 0.08) toward improved overall survival in patients treated with surgery versus those treated nonoperatively (median survival = 156 months versus 50 months). Patients with thymoma demonstrated a trend (p = 0.12) toward improved survival for over thymic carcinoma (median survival = 90 months versus 35 months). Conclusions. Treatment of patients with recurrent or progressive thymic tumors is associated with long-term survival. Despite the historical enthusiasm for re-resection, the majority of patients will recur again, therefore reoperation should be considered only in selected patients.
引用
收藏
页码:1984 / 1992
页数:9
相关论文
共 50 条
  • [31] Treatment experience of thymoma and thymic carcinoma in tertiary cancer institute in India
    Tirumala, V.
    Babu, M. C. Suresh
    Babu, K. Govind
    Lokanatha, D.
    Jacob, L. A.
    Lokesh, K. N.
    Rudresha, A. H.
    Rajeev, L. K.
    Saldanha, S. C.
    Giri, G. V.
    ANNALS OF ONCOLOGY, 2018, 29
  • [32] Treatment of Thymoma and Thymic Carcinoma with Proton Beam Therapy: Outcomes from the Proton Collaborative Group Prospective Registry
    Tian, S.
    McCook, A.
    Choi, I. J.
    Simone, C. B., II
    Vargas, C. E.
    Yu, N. Y.
    Chang, J. H. C.
    Mihalcik, S. A.
    Tsai, H.
    Zeng, J.
    Rosen, L. R.
    Rana, Z. H.
    Urbanic, J. J.
    Stokes, W. A.
    Kesarwala, A. H.
    Bradley, J. D.
    Higgins, K. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E66 - E66
  • [33] Thymoma, atypical thymoma, and thymic carcinoma - A novel conceptual approach to the classification of thymic epithelial neoplasms
    Suster, S
    Moran, CA
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1999, 111 (06) : 826 - 833
  • [34] MULTIMODAL APPROACH TO THE MANAGEMENT OF THYMOMA AND THYMIC CARCINOMA: MONO-INSTITUTIONAL EXPERIENCE
    Ascolese, A. M.
    Navarria, P.
    Clerici, E.
    Reggiori, G.
    Arcangeli, S.
    Pentimalli, S.
    Castiglioni, S.
    Alongi, F.
    Mancosu, P.
    Scorsetti, M.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S81 - S81
  • [35] Thymic Carcinoma: Outcomes After Surgical Resection
    Okereke, Ikenna C.
    Kesler, Kenneth A.
    Freeman, Richard K.
    Rieger, Karen M.
    Birdas, Thomas J.
    Ascioti, Anthony J.
    Badve, Sunil
    Nelson, Robert P.
    Loehrer, Patrick J.
    ANNALS OF THORACIC SURGERY, 2012, 93 (05): : 1668 - 1673
  • [36] The Impact of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma
    Jackson, Matthew W.
    Palma, David A.
    Camidge, D. Ross
    Jones, Bernard L.
    Robin, Tyler R.
    Sher, David J.
    Koshy, Matthew
    Kavanagh, Brian D.
    Gaspar, Laurie E.
    Rusthoven, Chad G.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (04) : 734 - 744
  • [37] Outcome of the sixteen thymoma and thymic carcinoma patients
    Arslan, Ulku Y.
    Utkan, Gungor
    Durnali, Ayse G.
    Celenkoglu, Gokhan
    Kocer, Murat
    Tokluoglu, Saadet
    Muallaoglu, Sadik
    Ozturk, Murat
    Alkis, Necati
    ANNALS OF ONCOLOGY, 2006, 17 : 167 - 167
  • [38] Recurrent genetic aberrations in thymoma and thymic carcinoma
    Zettl, A
    Ströbel, P
    Wagner, K
    Katzenberger, T
    Ott, G
    Rosenwald, A
    Peters, K
    Krein, A
    Semik, M
    Müller-Hermelink, HK
    Marx, A
    AMERICAN JOURNAL OF PATHOLOGY, 2000, 157 (01): : 257 - 266
  • [39] DEVELOPMENT OF GENE SIGNATURES FOR THYMOMA AND THYMIC CARCINOMA
    Badve, Sunil
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : 8 - 9
  • [40] Thymoma and thymic carcinoma in the target therapies era
    Lamarca, Angela
    Moreno, Victor
    Feliu, Jaime
    CANCER TREATMENT REVIEWS, 2013, 39 (05) : 413 - 420